Research Article
Expression and Clinical Significance of Plasma miR-223 in Patients with Diabetic Nephropathy
Table 2
Comparisons of basic clinical data in three groups.
| | Characteristic | Healthy control group (n = 17) | T2DM group (n = 19) | DN group (n = 20) | value |
| | Male, n (%) | 8 (47.1%) | 9 (47.4%) | 11 (55.0%) | 0.949 | | Age (years) | 49.6 ± 12.5 | 54.9 ± 14.2 | 56.3 ± 12.7 | 0.300 | | Disease duration (years) | 0 | 5.2 ± 1.5 | 6.8 ± 1.3 | 0.086 | | BMI (kg/m2) | 24.0 ± 5.9 | 25.3 ± 4.5 | 24.4 ± 4.3 | 0.720 | | FBG (mmol/L) | 5.2 ± 0.7 | 16.1 ± 8.1 | 12.9 ± 6.2 | <0.001 | | A1c (%) | 5.3 ± 0.48 | 10.8 ± 3.11 | 10.4 ± 2.81 | <0.001 | | uACR (mg/g) | 0.9 ± 0.8 | 2.1 ± 2.8 | 294.1 ± 271.2 | <0.001 | | Cr (umol/L) | 46.6 ± 6.8 | 62.1 ± 13.9 | 151.7 ± 120.4 | <0.001 | | eGFR (ml/min) | 111 ± 48.1 | 95.9 ± 35.3 | 74.4 ± 38.6 | 0.020 | | TG (mmol/L) | 1.5 ± 0.5 | 1.9 ± 0.6 | 2.7 ± 3.1 | 0.180 | | LDL-C (mmol/L) | 2.99 ± 0.72 | 3.49 ± 0.84 | 3.46 ± 1.60 | 0.353 | | Urine β2-MG (mg/L) | 2.0 ± 4.6 | 6.6 ± 13.7 | 7.0 ± 12.1 | 0.390 | | Urine α1-MG (mg/L) | 7.1 ± 9.4 | 19.2 ± 18.9 | 36.6 ± 34.5 | 0.003 | | Cys-C (mg/L) | 0.6 ± 0.1 | 0.9 ± 0.1 | 3.1 ± 0.9 | <0.001 |
|
|
BMI, body mass index; FBG, fasting blood glucose; A1c, glycated hemoglobin; uACR, urinary albumin-creatinine ratio; Cr, creatinine; eGFR, estimated glomerular filtration rate; TG, total glycerides; LDL-C, low-density lipid; α1-MG, α1-microglobulin; β2-MG, β2-microglobulin; Cyc-C, cystatin C.
|
